HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt

Coronary Arteriosclerosis Clinical Trial

— HARMONEE  

Official title:

Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE): Assessment of a Novel DES Platform For Percutaneous Coronary Revascularization in Patients With Ischemic Coronary Disease and NSTEMI Acute Coronary Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02073565
• Other study ID #: VP-0601
• Secondary ID: OMKK 02
• Status: Completed
• Phase: N/A
• Start date: February 2014
• Est. completion date: December 2021

Study information

• Verified date: April 2022
• Source: OrbusNeich
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multi-center, single-blind, randomized, active-controlled, clinical trial in Percutaneous Coronary Intervention (PCI) subjects. Subjects will be randomized to receive the Combo stent as the investigational treatment arm or an Everolimus Eluting Stent (EES) as the active-control arm.

Description:

Up to 50 sites are proposed in Japan and the United States to enroll 286 subjects (271 evaluable) in each of 2 arms, for a total sample size of 572 subjects (542 evaluable) who are admitted to the hospital for a planned (elective and urgent) percutaneous coronary artery intervention procedure.

After stent implantation, subjects will be contacted for follow-up at 30 days; 6 months; and 1, 2, 3, 4, and 5 years. At 12 months a clinical evaluation will be completed before cardiac catheterization and angiographic assessment.

Rationale: This study is intended to demonstrate that the Combo stent platform shows superiority to an imputed Bare Metal Stent (BMS) performance goal, noninferior effectiveness and safety vs best-in-class second-generation everolimus-eluting stent (EES) (Xience V, Xience Prime, Xience Xpedition stents; [Abbott Vascular/Abbott Vascular Japan]), and evidence of mechanistic activity of the anti-CD34-Ab endothelial progenitor cell (EPC) capture technology with healthy level of intimal tissue coverage superior to that of the best-in-class EES.

To ensure the robustness and interpretability of results, the current proposal includes a number of unique design features:

• Largest randomized Drug-Eluting Stent (DES) study ever performed in Japan

• Enriched population, including stabilized Non-ST-elevation myocardial infarction (NSTEMI) subjects with greater likelihood of plaque rupture associated with their clinical syndromes

• Collaboration between with Japan and the United States as a "Proof of Concept" program under the auspices of the Harmonization by Doing Initiative, Working Group 1 (WG 1), including concomitant enrollment in U.S.A. sites as an FDA-approved Investigational Device Exemption (IDE) study

• Head-to-head randomization against state-of-the-art EES platform control, analyzed for clinical noninferiority

• Statistical analysis vs imputed BMS analyzed for clinical superiority

• Fractional flow reserve (FFR) follow-up of 100% of subjects enrolled, providing clinically relevant physiologic assessment of all subjects for 1 year ischemia-driven Target Vessel Revascularization (TVR) analysis

• Mechanistic Optical coherence tomography (OCT) imaging observations in 140 subjects using 6 French catheters as follows:

• Cohort A (30 subjects, 1:1 Combo and EES): Mechanistic imaging observations to provide serial 6 month and 1 year OCT evaluation of healthy intimal tissue coverage, intracoronary thrombosis, and stent malapposition and quantitative coronary angiographic (QCA) analysis to assess 1 year late loss.

• Cohort B (110 subjects, 1:1 Combo and EES): Mechanistic imaging observations to assess 1 year OCT evaluation of healthy intimal tissue coverage, intracoronary thrombosis, and stent malapposition, and QCA analysis to assess 1 year late loss. Combined with the 12 month imaging of Cohort A, this study will provide OCT and QCA observations at 1 year in 140 patients, half with Combo and half with EES.

• Cohort C: 432 subjects (216 subjects per arm) will undergo all clinical follow-up assessments with FFR and angiographic assessments at 12 months. Cohort C will be the last cohort to enroll.

• In the 110 subjects in Cohort B, 30 day and 1 year human antimurine antibody (HAMA) titers will also be collected.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 572
• Est. completion date: December 2021
• Est. primary completion date: July 14, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria

To be eligible for this trial, subjects must meet all of the following criteria:

1. Subject is able to verbally confirm understanding of risks, benefits, and treatment alternatives of Combo vs EES stent, and the subject or a legally authorized representative (LAR) must provide written informed consent before any study-related procedures are performed.

2. Subject must be at least 20 years of age at the time of randomization.

3. Subject must have clinical or functional evidence of myocardial ischemia (eg, stable or unstable angina, stabilized non-ST-elevation myocardial infarction confirmed by serum markers, ischemia by positive functional study, abnormal FFR, or a reversible change in the electrocardiogram (ECG) consistent with ischemia).

4. Subject must be acceptable candidate with anatomy suitable for PCI with a DES.

5. Subject agrees to return for all study-related follow-up assessments, including invasive OCT follow-up assessment at 6 months (Cohort A) and at 1 year postprocedure (Cohorts A, B, and C).

6. Subject is an acceptable candidate for Coronary artery bypass grafting (CABG) surgery.

Angiographic Anatomy Criteria-

7. Target lesions must be located in a native coronary artery with visually estimated diameter of 2.5 mm to 3.5 mm, inclusive, and up to 3 de novo target lesions may be treated, with a maximum of 2 de novo target lesions per epicardial vessel, with a maximum of 2 target vessels.

8. Target lesions should be treatable with a single stent, and must measure 28 mm or less in length by visual estimation (2 mm or more of nondiseased tissue on either side of the target lesion should be covered by the study stent).

9. If more than 1 target lesion will be treated, the reference vessel diameter and lesion length of each target lesion must meet the above criteria.

10. Target lesions must be in a major artery or branch with a visually estimated stenosis of 50% or greater and less than 100% with a Thrombolysis in Myocardial Infarction (TIMI) flow of 1 or greater.

11. Previous percutaneous intervention of lesions in a target vessel (including side branches) is allowed if done 9 or more months before the study procedure and greater than 10 mm from the current target lesion.

12. Nonstudy percutaneous interventions for lesions in a nontarget vessel are allowed if done 9 or more months before the study procedure, in the absence of documented ischemia or angiographic restenosis related to the vessel.

Exclusion Criteria

If a subject meets any of the following criteria, he or she may not be enrolled in the study:

1. ST-Elevation Myocardial Infarction (STEMI) at index presentation or within 7 days of study screening.

2. Subject has current unstable arrhythmias or intractable angina with ECG changes or shock requiring pressors or mechanical assist device (intraaortic balloon pump, left ventricular assist device, Impella, etc.).

3. Subject has known left ventricular ejection fraction (LVEF) less than 30%.

4. Subject has received a heart transplant or any other organ transplant or is on a waiting list for any organ transplant.

5. Subject is receiving or scheduled to receive anticancer therapy for malignancy within 30 days before or after the procedure.

6. Subject is receiving immunosuppression therapy, has known serious immunosuppressive disease (eg, human immunodeficiency virus), or has severe autoimmune disease that requires chronic immunosuppressive therapy (eg, systemic lupus erythematosus).

7. Subject has known hypersensitivity or contraindication to aspirin; both heparin and bivalirudin; all available P2Y12 inhibitors (clopidogrel, prasugrel, ticlopidine, and ticagrelor); any everolimus, sirolimus, cobalt, chromium, nickel, tungsten, acrylic, or fluoro polymers; or hypersensitivity to contrast media that cannot be adequately premedicated.

8. Subject has previously received murine therapeutic antibodies and exhibited sensitization through the production of human anti-mouse antibodies (HAMAs).

9. Subject has elective surgery planned within the first 12 months after the procedure that will require interruption or discontinuation of planned Dual Antiplatelet Therapy (DAPT).

10. Subject has known platelet count less than 100,000 cells/mm3 or greater than 700,000 cells/mm3, a white blood cell count of less than 3000 cells/mm3, or documented or suspected liver disease (including laboratory evidence of hepatitis).

11. Subject has known renal insufficiency (eg, serum creatinine level of greater than 2.5 mg/dL or subject is on dialysis).

12. Subject has history of bleeding diathesis or coagulopathy or will refuse blood transfusions.

13. Subject has had a cerebrovascular accident or transient ischemic neurological attack within the past 6 months.

14. Subject has had a significant gastrointestinal or urinary bleed within the past 6 months.

15. Subject has known extensive peripheral vascular disease that precludes safe 6 French sheath insertion.

16. Known other medical illness (eg, cancer, chronic infectious disease, severe vascular disease, or congestive heart failure) or known history of substance abuse (alcohol, cocaine, heroin, etc.) that may cause noncompliance with the protocol, confound the data interpretation, or is associated with a life expectancy of less than 1 year.

17. Currently participating in another clinical study that has not yet reached its primary endpoint.

18. Currently pregnant or breast-feeding or is planning pregnancy in the period up to 1 year following index procedure. Female subjects of childbearing potential must have a negative pregnancy test within 7 days before the index procedure.

Angiographic Exclusion Criteria-

If the target lesion meets any of the following criteria, the subject may not be enrolled in the study:

19. Unprotected left main coronary artery location.

20. Unprotected ostial (located within 2 mm of the origin) left anterior descending artery or left circumflex.

21. Located within an arterial or saphenous vein graft or graft anastomosis, distal to a diseased arterial or saphenous vein graft (visually estimated graft diameter stenosis greater than 40%).

22. Involves a bifurcation in which the side branch is 2 mm or greater in diameter AND would be covered by the planned stent.

23. Involves a side branch requiring predilation.

24. Total occlusion (TIMI flow 0) before wire crossing.

25. Extreme tortuosity proximal to or within the lesion.

26. Extreme angulation (90º or greater) proximal to or within the lesion.

27. Heavy calcification, defined as multiple persisting opacifications of the coronary wall visible in more than one projection surrounding the complete lumen of the coronary artery at the site of the lesion.

28. Restenotic vessel from previous intervention.

29. Received brachytherapy in any epicardial vessel (including side branches).

30. Target vessel contains angiographically visible thrombus.

31. Serial lesions or diffuse disease with high probability of bailout requiring 3 or more stents in a single vessel, more than 5 stents per subject, or more than 2 vessels.

32. Target or nontarget vessel lesion (including all side branches) is present with a high probability of requiring PCI within 12 months after the index procedure.

33. Stent overlapping is a planned treatment of the target lesion.

Related Conditions & MeSH terms

• Acute Coronary Syndrome
• Arteriosclerosis
• Coronary Arteriosclerosis
• Coronary Artery Disease
• Myocardial Ischemia
• Non ST Segment Elevation Acute Coronary Syndrome
• Syndrome

Intervention

Device:
• OrbusNeich Combo stent™
The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
• Everolimus Eluting Stent (EES)
Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.

Locations

Country	Name	City	State
Japan	Department of Cardiovascular Medicine, Juntendo University School of Medicine	Bunkyo-ku	Tokyo
Japan	Sakakibara Memorial Hospital	Fuchu-shi	Tokyo
Japan	Saiseikai Fukuoka General Hospital	Fukoka-shi	Fukuoka
Japan	Hakodate Municipal Hospital	Hakodate-shi	Hokkaido
Japan	Hyogo Brain and Heart Centre	Himeji-shi	Hyogo
Japan	Tsuchiya General Hospital	Hiroshima-shi	Hiroshima
Japan	Teikyo University Hospital	Itabashi-ku	Tokyo
Japan	National Hospital Organisation Kagoshima Medical Centre	Kagoshima-shi	Kagoshima
Japan	Kanazawa Cardiovascular Hospital	Kanazawa-shi	Ishikawa
Japan	Kanto Rosai Hospital	Kawasaki-shi	Kanagawa
Japan	Takahashi Hospital	Kobe-shi	Hyogo
Japan	Saitama Prefectural Cardiovascular and Respiratory Disease Centre	Kumagaya-shi	Saitama-ken
Japan	Kurashiki Central Hospital	Kurashiki-shi	Okayama
Japan	Kurume University Hospital	Kurume-shi	Fukuoka
Japan	Shinkoga Hospital	Kurume-shi	Fukuoka
Japan	Kyoto-Katsura Hospital	Kyoto-shi	Kyoto
Japan	Toho University Ohashi Hospital	Meguro-ku	Tokyo
Japan	The Cardiovascular Institute Hospital	Minato-ku	Tokyo
Japan	Miyazaki Medical Association Hospital	Miyazaki-shi	Miyazaki
Japan	Shonan Kamakura General Hospital	Okamoto	Kamakura City
Japan	The Sakakibara Heart Institute of Okayama	Okayama-shi	Okayama
Japan	Osaka Saiseikai Nakatsu Hospital	Osaka-shi	Osaka
Japan	Sakurabashi Watanabe Hospital	Osaka-shi	Osaka
Japan	Saga University Hospital	Saga-shi	Saga
Japan	Sapporo Higashi Tokushukai Hospital	Sapporo-shi	Hokkaido
Japan	Jichi Medical University Hospital	Shimotsuke-shi	Tochigi
Japan	Showa University Hospital	Shinagawa-ku	Tokyo
Japan	Cardiac Catheterisation Laboratory, Keio University School of Medicine	Shinjuku-ku	Tokyo
Japan	Tokyo Women's Medical University Hospital	Shinjuku-ku	Tokyo
Japan	Okamura Memorial Hospital	Suntou-gun	Shizouka
Japan	Higashi Takarazuka Satoh Hospital	Takarazukasi	Hyogo
Japan	Tsuchiura Kyodo Hospital	Tsuchiura	Ibaraki
Japan	Saiseikai Yokohamashi Tobu Hospital	Yokohama-shi	Kanagawa
United States	Lehigh Valley Hospital	Allentown	Pennsylvania
United States	Emory University Hospital Midtown	Atlanta	Georgia
United States	Lahey Clinic	Burlington	Massachusetts
United States	The Ohio State University Medical Center	Columbus	Ohio
United States	Duke University Medical Center	Durham	North Carolina
United States	North Georgia Heart Foundation	Gainesville	Georgia
United States	Atlantic Clinical Research Collaborative-Cardiology	Lake Worth	Florida
United States	University of Miami	Miami	Florida
United States	Vanderbilt University Medical Center	Nashville	Tennessee
United States	Mount Sinai Medical Center	New York	New York
United States	Maine Medical Center	Portland	Maine
United States	University of Rochester Medical Center-Strong Memorial Hospital	Rochester	New York
United States	Washington Adventist Hospital	Takoma Park	Maryland
United States	Tallahassee Research Institute	Tallahassee	Florida
United States	North Mississippi Medical Center	Tupelo	Mississippi
United States	MedStar Clinical Research Center	Washington	District of Columbia
United States	Wake Forest Baptist Medical Center	Winston-Salem	North Carolina

Sponsors (3)

Lead Sponsor	Collaborator
OrbusNeich	Duke Clinical Research Institute, OrbusNeich Medical K.K.

Countries where clinical trial is conducted

United States,  Japan, 

References & Publications (2)

Kong DF, Saito S, Nakamura S, Mehran R, Rowland SM, Handler A, Al-Khalidi HR, Krucoff MW. Rationale and design of the Japan-USA harmonized assessment by randomized, multicenter study of OrbusNEich's combo StEnt (Japan-USA HARMONEE): Assessment of a novel DES platform for percutaneous coronary revascularization in patients with ischemic coronary disease and non-ST-elevation acute coronary syndrome. Am Heart J. 2017 May;187:112-121. doi: 10.1016/j.ahj.2017.02.004. Epub 2017 Feb 12. — View Citation

Saito S, Krucoff MW, Nakamura S, Mehran R, Maehara A, Al-Khalidi HR, Rowland SM, Tasissa G, Morrell D, Joseph D, Okaniwa Y, Shibata Y, Bertolet BD, Rothenberg MD, Généreux P, Bezerra H, Kong DF. Japan-United States of America Harmonized Assessment by Rand — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number of Patients With Clinically and Functionally Ischemia-Driven Target Lesion Revascularization (TLR)	Clinically and functionally ischemia-driven target lesion revascularization (TLR), including use of target-vessel Fractional Flow Reserve (FFR), analyzed dichotomously using the Fractional Flow Reserve (FFR) vs. Angiography in Multivessel Evaluation (FAME) study criteria of 0.8 during a 2 minute infusion of adenosine or adenosine triphosphate.34 Abnormal FFR-driven interventions at 1 year will be included in the evaluation of ischemia-driven TLR.	1 year
Other	Number of Patients Exhibiting Human Antimurine Antibody (HAMA) Reaction	Serum will be assessed for HAMA development at index, 30 days, and 12 months in Cohort B subjects. Human antimurine antibody plasma assessment will be with blood draws performed during index procedure, 30 day follow-up visit, and 1 year catheterizations.	Day of device implantation, 30 days, 12 months
Primary	Number of Participants With Target Vessel Failure (TVF)	The primary clinical endpoint of Target Vessel Failure (TVF), defined as cardiac death, target-vessel myocardial infarction (MI), or ischemia-driven Target Vessel Revascularization(TVR) by percutaneous or surgical methods, at 1 year.	1 year follow-up
Secondary	Percentage of Healthy Tissue Coverage That Was Greater Than 40 Micrometers	The secondary efficacy endpoint is mechanistic Optical coherence tomography (OCT) healthy level of intimal tissue coverage, determined by the OCT core laboratory at 1 year for subjects in Cohorts A and B. This reports the percentage of healthy tissue coverage that was great than 40 micrometers.	1 year